Fungal microbiota dysbiosis in IBD: A study of 235 IBD patients and 38 healthy subjects revealed significant alterations in the fungal microbiota compared to healthy individuals. The fungal microbiota in IBD patients showed an increased Basidiomycota/Ascomycota ratio, a decreased proportion of Saccharomyces cerevisiae, and an increased proportion of Candida albicans. The study also identified disease-specific alterations in fungal microbiota diversity, suggesting that a Crohn's disease-specific gut environment may favor fungi over bacteria. The analysis of bacterial and fungal microbiota showed a dense and homogenous correlation network in healthy subjects but a dramatically unbalanced network in IBD, indicating disease-specific inter-kingdom alterations. The study identified a distinct fungal microbiota dysbiosis in IBD characterized by changes in biodiversity and composition. Additionally, the study found disease-specific inter-kingdom network alterations in IBD, suggesting that fungi may also play a role in IBD pathogenesis. The results support the role of fungal microbiota in IBD pathogenesis and indicate a new potential therapeutic target. The study also found that S. cerevisiae and C. albicans may have protective and worsening roles in the inflammatory process, respectively. The study highlights the importance of understanding the role of fungi in IBD and suggests that fungi could be a new therapeutic target in the treatment of IBD. The study also found that the fungal microbiota in IBD patients showed a decreased biodiversity, with a decrease in some bacteria from the Firmicutes phylum and an increase in bacteria from the Proteobacteria phylum. The study also found that the fungal microbiota in IBD patients showed a higher ratio of Basidiomycota to Ascomycota, which could represent a fungal dysbiosis index. The study also found that the abundance of S. cerevisiae was decreased in IBD patients, particularly in flare, and that the abundance of C. albicans was increased in IBD flare compared to remission. The study also found that the abundance of S. cerevisiae was independently associated with IBD and flare. The study also found that the abundance of C. albicans was increased in IBD patients. The study suggests that fungi may play a role in IBD pathogenesis and that the fungal microbiota could be a new therapeutic target. The study also found that the fungal microbiota in IBD patients showed a disease-specific pattern with a higher number of significant correlations in UC compared to HS. The study also found that the fungal microbiota in IBD patients showed a higher number of significant correlations in UC compared to HS. The study also found that the fungal microbiota in IBD patients showed a higher number of significant correlations in UC compared to HS. The study also found that the fungal microbiota in IBD patients showed a higher number of significant correlations in UC compared to HS. The study also found that theFungal microbiota dysbiosis in IBD: A study of 235 IBD patients and 38 healthy subjects revealed significant alterations in the fungal microbiota compared to healthy individuals. The fungal microbiota in IBD patients showed an increased Basidiomycota/Ascomycota ratio, a decreased proportion of Saccharomyces cerevisiae, and an increased proportion of Candida albicans. The study also identified disease-specific alterations in fungal microbiota diversity, suggesting that a Crohn's disease-specific gut environment may favor fungi over bacteria. The analysis of bacterial and fungal microbiota showed a dense and homogenous correlation network in healthy subjects but a dramatically unbalanced network in IBD, indicating disease-specific inter-kingdom alterations. The study identified a distinct fungal microbiota dysbiosis in IBD characterized by changes in biodiversity and composition. Additionally, the study found disease-specific inter-kingdom network alterations in IBD, suggesting that fungi may also play a role in IBD pathogenesis. The results support the role of fungal microbiota in IBD pathogenesis and indicate a new potential therapeutic target. The study also found that S. cerevisiae and C. albicans may have protective and worsening roles in the inflammatory process, respectively. The study highlights the importance of understanding the role of fungi in IBD and suggests that fungi could be a new therapeutic target in the treatment of IBD. The study also found that the fungal microbiota in IBD patients showed a decreased biodiversity, with a decrease in some bacteria from the Firmicutes phylum and an increase in bacteria from the Proteobacteria phylum. The study also found that the fungal microbiota in IBD patients showed a higher ratio of Basidiomycota to Ascomycota, which could represent a fungal dysbiosis index. The study also found that the abundance of S. cerevisiae was decreased in IBD patients, particularly in flare, and that the abundance of C. albicans was increased in IBD flare compared to remission. The study also found that the abundance of S. cerevisiae was independently associated with IBD and flare. The study also found that the abundance of C. albicans was increased in IBD patients. The study suggests that fungi may play a role in IBD pathogenesis and that the fungal microbiota could be a new therapeutic target. The study also found that the fungal microbiota in IBD patients showed a disease-specific pattern with a higher number of significant correlations in UC compared to HS. The study also found that the fungal microbiota in IBD patients showed a higher number of significant correlations in UC compared to HS. The study also found that the fungal microbiota in IBD patients showed a higher number of significant correlations in UC compared to HS. The study also found that the fungal microbiota in IBD patients showed a higher number of significant correlations in UC compared to HS. The study also found that the